GH Research announces acceptance of presentation at ASCP

GH Research (GHRS) announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting, ASCP, in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression. “The findings from this double-blind, placebo-controlled Phase 2b trial are truly exciting and – if replicated in larger trials – could prove to be a transformative leap in our efforts to help people with treatment-resistant depression. In clinical research there’s a hierarchy of evidence and this well-controlled trial delivers robust evidence of the treatment’s efficacy and safety. These findings build on prior successes studying drugs formerly pigeonholed as “psychedelics” and bring us closer to offering real hope to patients who have exhausted other options,” said Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania.